Induction Chemotherapy in Combination with Bevacizumab for Stage IV Lung Cancer: Report of a Curative Resection Case

概要

論文の詳細を見る
Background. Bevacizumab in combination chemotherapy has improved tumor regression rate in the treatment of advanced non-squamous non-small cell lung cancer (NSCLC). Case. A 78-year-old man was given a diagnosis of primary lung cancer in the left upper lobe with a left adrenal metastasis (adenocarcinoma, cT2aN0M1b, stage IV) and received 4 cycles of bevacizumab combination chemotherapy. After chemotherapy, 75% tumor reduction rate (partial response) was achieved and tumor marker values normalized. Therefore, left upper lobectomy and left adrenalectomy were performed. In the primary tumor Ef. 2 (viable cancer cells seen in less than one-third of the tumor) was observed, with Ef. 3 in the previous metastatic tumor (no viable cancer cells in histological observation). He has been well with no evidence of recurrence for 12 months after operation. Conclusion. Induction chemotherapy in combination with bevacizumab may increase the indications for current unresectable advanced NSCLC, based on careful case selection.